We are monitoring the impact of COVID-19 on Latin America Multiple Sclerosis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date October, 2021
ID: 12254
Share on
Share on

Latin America Multiple Sclerosis Drugs Market Research Report - Segmented By Drug class, Disease type, Route of administration, Distribution channel, and Country (Brazil, Argentina, Chile, Mexico and Rest of Latin America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: October, 2021
ID: 12254
Pages: 120

Latin America Multiple Sclerosis Drugs Market Size (2021 to 2026)

The Latin America multiple sclerosis drugs market size is estimated to reach USD 2.80 billion by 2026. In 2021, the market was sized at USD 1.88 billion, at a CAGR of 8.31% during 2021-2026.

Multiple sclerosis is a chronic, inflammatory, autoimmune disease that affects the central nervous system (CNS), particularly the communication between the brain and other areas of the body. Multiple sclerosis (MS) in particular is a demyelinating disease that damages the insulating linings of nerve cells in the brain and spinal cord.

The Latin American multiple sclerosis drugs market growth is attributed to several key factors, including an increase in the prevalence of multiple sclerosis and an increase in funding for multiple sclerosis research. In addition, multiple sclerosis is becoming more common at an alarming rate, posing a threat to health care, professionals, and the government. Because of the disease’s increasing prevalence, the government has been forced to implement preventative measures in guidelines and recommendations. Aside from that, government organizations are launching many public awareness campaigns to inform patients about several treatment options available.

Multiple sclerosis is growing more common, and funding for disease research is expanding, propelling the multiple sclerosis medicines market ahead. As a result of increased financing, significant research is being performed on developing new medicines and therapies for multiple sclerosis and innovative approaches for detecting probable causes of multiple sclerosis. In addition, companies have made various attempts to develop novel multiple sclerosis medicines, driving the market.

Furthermore, a number of other factors, including genetic and environmental factors, contribute to the increased occurrence of multiple sclerosis. Multiple sclerosis has also been linked to the development of autoimmune disorders such as Type 1 diabetes and infections such as infectious mononucleosis. Therefore, the need for multiple sclerosis treatments is expected to increase in the coming years as the disease’s prevalence rises, leading to the market’s expansion. Demand for multiple sclerosis medications has increased as the prevalence of the disease has increased, resulting in market expansion. In addition, product demand would rise as per capita health expenditure rises, boosting the Latin America multiple sclerosis drugs market expansion.

However, The high cost of medicines used to treat multiple sclerosis will have a negative impact on the growth rate of multiple sclerosis drugs during the forecast period.

This research report on the Latin America multiple sclerosis drugs market has been segmented & sub-segmented into the following categories:

 By Drug Class:

  • Interferon Beta
  • Sphingosine 1 Phosphate Receptor Modulators
  • Mixed Polymers
  • NF-κB Inhibitor
  • Pyrimidine Synthesis Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Adrenocorticotropic Hormone
  • Others

By Disease Type:

  • Relapsing-remitting MS (RRMS)
  • Primary-progressive MS (PPMS)
  • Secondary-progressive MS (SPMS)
  • Progressive-relapsing MS (PRMS)

By Route of Administration:

  • Parenteral
  • Oral

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Country:

  • Brazil
  • Argentina
  • Chile
  • Mexico
  • Rest of Latin America

The Latin America multiple sclerosis drugs market is projected to witness a moderate share during the forecast period. The market growth is expected to be driven by several important causes, including greater population awareness of multiple sclerosis and innovative products. In addition, some prominent driving aspects for the market’s growth include the rising prevalence of multiple sclerosis and increased financing for multiple sclerosis research. As a result, Brazil, Argentina, Mexico, Chile, and the rest of the Latin American regions are contributing to the regional multiple sclerosis drugs market.

According to the data released by the Brazilian Congress of Neurology, the average prevalence of multiple sclerosis disease in Brazil in 2020 was 8.69 per 100,000 people. As a result, the market for multiple sclerosis drugs in Latin America is developing due to the rising prevalence of the disease. Furthermore, extensive research is being carried out on creating novel drugs and therapies for multiple sclerosis and alternative techniques of potential causes of multiple sclerosis caused by an increase in financing across Latin America.

At the Centro de Esclerosis Multiple Buenos Aires, Argentina, a study named “Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina” was done. As the number of COVID-19 patients in the region grows exponentially, there is a growing demand for data showing the impact of the novel coronavirus on multiple sclerosis.

KEY MARKET PLAYERS:

Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA) and AbbVie, Inc. are a few of the promising companies operating in the Latin America multiple sclerosis drugs market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Multiple Sclerosis Drugs Market – By Drug Class:                       

                        6.1.1   Interferon Beta

                        6.1.2 Sphingosine 1 Phosphate Receptor Modulators          

                        6.1.3   Mixed Polymers          

                        6.1.4  NF-κB Inhibitor 

                        6.1.5  Pyrimidine Synthesis Inhibitor 

                        6.1.6  Monoclonal Antibodies

                        6.1.7 Corticosteroids 

                        6.1.8 Adrenocorticotropic Hormone 

                        6.1.9 Others   

                        6.1.10 Market Size Estimations & Forecasts (2021-2026)    

                        6.1.11 Y-o-Y Growth Rate Analysis    

                        6.1.12 Market Attractiveness Index  

            6.2 Multiple Sclerosis Drugs Market – By Disease Type:                  

                        6.2.1 Relapsing-remitting MS (RRMS)

                        6.2.2 Primary-progressive MS (PPMS)          

                        6.2.3 Secondary-progressive MS (SPMS)      

                        6.2.4    Progressive-relapsing MS (PRMS)      

                        6.2.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.6 Y-o-Y Growth Rate Analysis      

                        6.2.7 Market Attractiveness Index    

            6.3 Multiple Sclerosis Drugs Market – By Route of Administration:             

                        6.3.1  Parenteral        

                        6.3.2   Oral     

                        6.3.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.4 Y-o-Y Growth Rate Analysis      

                        6.3.5 Market Attractiveness Index    

            6.4 Multiple Sclerosis Drugs Market – By Distribution Channel:                  

                        6.4.1    Hospital Pharmacies  

                        6.4.2  Retail Pharmacies & Drug Stores         

                        6.4.3 Online Pharmacies        

                        6.4.4 Market Size Estimations & Forecasts (2021-2026)      

                        6.4.5 Y-o-Y Growth Rate Analysis      

                        6.4.6 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1. Latin America                   

                        7.1.1 By Country        

                                    7.1.1.1 Brazil

                                    7.1.1.2 Argentina

                                    7.1.1.3 Mexico

                                    7.1.1.4 Rest of Latin America

                        7.1.2  By Drug Class:  

                        7.1.3 By Disease Type:           

                        7.1.4 By Route of Administration:     

                        7.1.5 By Distribution Channel:          

8. Key Player Analysis                        

            8.1 Bayer AG              

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Teva Pharmaceutical Industries Ltd.                   

            8.3  Novartis AG                     

            8.4 Sanofi                   

            8.5  F. Hoffmann-La Roche Ltd.                     

            8.6 Celgene Corporation                   

            8.7 Acorda Therapeutics, Inc.            

            8.8 Biogen, Inc.                      

            8.9 Actelion Pharmaceuticals (Johnson & Johnson)             

            8.10 EMD Serono (Merck KGaA)                   

            8.11 AbbVie, Inc.                    

9. Market Outlook & Investment Opportunities                               

10. Appendix                          

            List of Tables              

            List of Figures  

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of drug class, disease type, route of administration, distribution channel and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Latin America multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  2. Latin America Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )

  3. Latin America Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )

  4. Latin America   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )

  5. Latin America NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )

  6. Latin America Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )

  7. Latin America Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )

  8. Latin America Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )

  9. Latin America Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )

  10. Latin America  Others Market By Region, From 2021 to 2026 ( USD Billion )

  11. Latin America multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  12. Latin America Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )

  13. Latin America Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )

  14. Latin America  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )

  15. Latin America Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )

  16. Latin America multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  17. Latin America Parenteral Market By Region, From 2021 to 2026 ( USD Billion )

  18. Latin America Oral Market By Region, From 2021 to 2026 ( USD Billion )

  19. Latin America multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  20. Latin America Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  21. Latin America Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )

  22. Latin America  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  23. Brazil multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  24. Brazil multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  25. Brazil multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  26. Brazil multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  27. Argentina multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  28. Argentina multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  29. Argentina multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  30. Argentina multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  31. Mexico multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  32. Mexico multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  33. Mexico multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  34. Mexico multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  35. Rest of Latin America multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )

  36. Rest of Latin America multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )

  37. Rest of Latin America multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )

  38. Rest of Latin America multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample